Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast

Cancer

Volumn 119, Issue 1, 2013, Pages 150-157

  Bailes, Adele A ^a,b   Kuerer, Henry M ^a   Lari, Sara A ^a   Jones, Lovell A ^b   Brewster, Abenaa M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

breast cancer; ductal carcinoma in situ; ethnicity; health care disparity; race; recurrence

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; BREAST CARCINOGENESIS; BREAST NECROSIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; CLINICAL FEATURE; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; FAMILY HISTORY; FEMALE; FOLLOW UP; HEALTH DISPARITY; HISPANIC; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; ONSET AGE; PACIFIC ISLANDER; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECURRENCE RISK; TREATMENT OUTCOME; TUMOR VOLUME;

AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872797045     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27707     Document Type: Article

References (28)

1. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009; 27: 279-288.
2. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA,. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006; 24: 1342-1349.
3. Newman LA, Martin IK,. Disparities in breast cancer. Curr Probl Cancer. 2007; 31: 134-156.
4. Amirikia KC, Mills P, Bush J, Newman LA,. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer. 2011; 117: 2747-2753.
5. Deshpande AD, Jeffe DB, Gnerlich J, Iqbal AZ, Thummalakunta A, Margenthaler JA,. Racial disparities in breast cancer survival: an analysis by age and stage. J Surg Res. 2009; 153: 105-113.
6. Nassar H, Sharafaldeen B, Visvanathan K, Visscher D,. Ductal carcinoma in situ in African American versus Caucasian American women: analysis of clinicopathologic features and outcome. Cancer. 2009; 115: 3181-3188.
7. Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL,. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010; 2010: 121-129.
8. Innos K, Horn-Ross PL,. Recent trends and racial/ethnic differences in the incidence and treatment of ductal carcinoma in situ of the breast in California women. Cancer. 2003; 97: 1099-1106.
9. Zujewski JA, Harlan LC, Morrell DM, Stevens JL,. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat. 2010; 127: 251-257.
10. Li CI, Malone KE, Saltzman BS, Daling JR,. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006; 106: 2104-2112.
11. Pocock B, Nash S, Klein L, El-Tamer M, Schnabel FR, Joseph KA,. Disparities in time to definitive surgical treatment between black and white women diagnosed with ductal carcinoma in situ. Am J Surg. 2007; 194: 521-523.
12. Kaplan CP, Napoles AM, Hwang ES, et al. Selection of treatment among Latina and non-Latina white women with ductal carcinoma in situ. J Womens Health (Larchmt). 2011; 20: 215-223.
13. Livaudais JC, Hwang ES, Karliner L, et al. Adjuvant hormonal therapy use among women with ductal carcinoma in situ. J Womens Health (Larchmt). 2012; 21: 35-42.
14. Chuwa EW, Tan VH, Tan PH, Yong WS, Ho GH, Wong CY,. Treatment for ductal carcinoma in situ in an Asian population: outcome and prognostic factors. ANZ J Surg. 2008; 78: 42-48.
15. Baxter NN, Virnig BA, Durham SB, Tuttle TM,. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004; 96: 443-448.
16. Polednak AP,. How frequent is postmastectomy breast reconstructive surgery? A study linking two statewide databases. Plast Reconstr Surg. 2001; 108: 73-77.
17. Alderman AK, McMahon L, Wilkins EG,. The national utilization of immediate and early delayed breast reconstruction and the effect of sociodemographic factors. Plast Reconstr Surg. 2003; 111: 695-703.
18. Kruper L, Xu X, Henderson K, Bernstein L,. Disparities in reconstruction rates after mastectomy for ductal carcinoma in situ (DCIS): patterns of care and factors associated with the use of breast reconstruction for DCIS compared with invasive cancer. Ann Surg Oncol. 2011; 18: 3210-3219.
19. Desantis C, Siegel R, Bandi P, Jemal A,. Breast cancer statistics, 2011. CA Cancer J Clin. 2011; 61: 409-418.
20. American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Atlanta, GA: American Cancer Society; 2011.
21. Joslyn SA,. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J. 2006; 12: 20-27.
22. Virnig BA, Tuttle TM, Shamliyan T, Kane RL,. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010; 102: 170-178.
23. Warren JL, Weaver DL, Bocklage T, et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population-based analysis. Cancer. 2005; 104: 1840-1848.
24. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ,. Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med. 2006; 8: 571-575.
25. Claus EB, Petruzella S, Matloff E, Carter D,. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005; 293: 964-969.
26. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, et al. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012; 118: 1515-1522.
27. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676-689.
28. King MC, Marks JH, Mandell JB,. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302: 643-646.